Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | Director · Chairman & CEO · 10% owner | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 449,019 |
Ending reported balance
After 2026-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-05 · Exercise / conversion · Acquired 4,109 · Balance 450,294 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 2 · 2026-09-05 · Tax withholding · Disposed 2,876 · Balance 447,418 Row 3 · 2026-09-06 · Exercise / conversion · Acquired 3,455 · Balance 450,873 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 4 · 2026-09-06 · Tax withholding · Disposed 1,854 · Balance 449,019 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 17,251 |
Reported balance
After 2026-09-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-09-04 · Grant · Acquired 17,251 · Balance 17,251 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,330 |
Reported balance
After 2026-09-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-09-05 · Exercise / conversion · Disposed 4,109 · Balance 12,330 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,912 |
Reported balance
After 2026-09-06 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-09-06 · Exercise / conversion · Disposed 3,455 · Balance 6,912 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| Bio-Rad B Common StockSEC Table I · non-derivative | Direct | 361,466 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 361,466 |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy Spouse | 13,006 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 13,006 F2: The reporting person disclaims beneficial ownership of these shares. |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy Blue Raven Partners, L.P. | 4,060,054 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 4,060,054 F3: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy Alice N. Schwartz Revocable Trust | 1,781,356 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,781,356 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Exemption Trust | 90 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 90 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Exempt Martial Trust | 240 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 240 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Non-Exempt Martial Trust | 898,931 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 898,931 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy David Schwartz Non-Exempt Martial Trust | 57,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 57,000 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad A Common StockSEC Table I · non-derivative | IndirectBy Charitable Remainder Unitrust | 34,311 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 34,311 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Bio-Rad B Common StockSEC Table I · non-derivative | IndirectBy Alice N. Schwartz Revocable Trust | 437,510 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 437,510 F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: The reporting person disclaims beneficial ownership of these shares.
F3: The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F4: The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F6: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
F7: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 06, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 3,455 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · derivative · entry 17 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,912 Underlying: Bio-Rad A Common Stock · 3,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F7 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 06, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,854 | $386.11 | $715,847.94 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,019 Read SEC document |
| September 06, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,455 | $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 4,109 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · derivative · entry 16 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,330 Underlying: Bio-Rad A Common Stock · 4,109 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F7 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 2,876 | $386.11 | $1,110,452.36 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,418 Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 4,109 | $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 22:42 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 17,251 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000004 · wk-form4_1788993728.xml · derivative · entry 15 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,251 Underlying: Bio-Rad A Common Stock · 17,251 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. F6 · derivative.expiration_date: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000002 · wk-form4_1788471355.xml · derivative · entry 14 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,005 Underlying: Bio-Rad A Common Stock · 3,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,082 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000002 · wk-form4_1788471355.xml · derivative · entry 13 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,082 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 2,336 | $380.96 | $889,922.56 |
DisclosureSEC source: 0000940805-26-000002 · wk-form4_1788471355.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,185 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 5,087 | $0.00 | $0.00 |
DisclosureSEC source: 0000940805-26-000002 · wk-form4_1788471355.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 448,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 3,455 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000006 · wk-form4_1757449196.xml · derivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,367 Underlying: Bio-Rad A Common Stock · 3,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,528 | $295.43 | $451,417.04 |
DisclosureSEC source: 0000940805-25-000006 · wk-form4_1757449196.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,434 Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,455 | $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000006 · wk-form4_1757449196.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:19 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 16,439 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000006 · wk-form4_1757449196.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,439 Underlying: Bio-Rad A Common Stock · 16,439 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F5 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:00 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000004 · wk-form4_1756936850.xml · derivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010 Underlying: Bio-Rad A Common Stock · 3,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:00 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,082 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000004 · wk-form4_1756936850.xml · derivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,082 Underlying: Bio-Rad A Common Stock · 2,082 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:00 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,266 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000004 · wk-form4_1756936850.xml · derivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 1,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:00 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 3,084 | $297.88 | $918,661.92 |
DisclosureSEC source: 0000940805-25-000004 · wk-form4_1756936850.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,507 Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 22:00 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 6,353 | $0.00 | $0.00 |
DisclosureSEC source: 0000940805-25-000004 · wk-form4_1756936850.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:03 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,671 | $0.00 Strike: $256.45 | $0.00 |
DisclosureSEC source: 0001062993-25-004609 · form4.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,671 Underlying: Bio-Rad A Common Stock · 11,671 shares Expires 2035-03-03 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 18:07 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 13,822 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016388 · form4.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,822 Underlying: Bio-Rad A Common Stock · 13,822 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · derivative · entry 18 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F9 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,241 | $334.31 | $414,878.71 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 10 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,238 Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 9 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 439,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,805 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · derivative · entry 17 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 1,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F8 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 965 | $337.32 | $325,513.80 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,159 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,266 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · derivative · entry 16 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,266 Underlying: Bio-Rad A Common Stock · 1,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 2,081 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · derivative · entry 15 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,164 Underlying: Bio-Rad A Common Stock · 2,081 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · derivative · entry 14 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,015 Underlying: Bio-Rad A Common Stock · 3,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 545 | $337.32 | $183,839.40 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,319 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 801 | $337.32 | $270,193.32 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,598 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 2,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 1,607 | $337.32 | $542,073.24 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,318 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:35 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 3,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-016174 · form4.xml · nonDerivative · entry 1 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015816 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 13,006 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 23:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 57 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015816 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,466 Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 16:23 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 14,137 | $0.00 Strike: $343.76 | $0.00 |
DisclosureSEC source: 0001062993-24-006216 · form4.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,137 Underlying: Bio-Rad A Common Stock · 14,137 shares Expires 2034-03-08 F3 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022114 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 12,949 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these shares. Read SEC document |
| December 05, 2023 Filed Dec 8, 2023 00:14 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GiftBio-Rad B Common Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022114 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,409 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $159.32 | $0.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · derivative · entry 12 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 15,000 shares Expires 2026-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 15,000 shares, became exercisable in five equal annual installments beginning on September 7, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $139.56 | $0.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · derivative · entry 11 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 16,000 shares Expires 2025-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 16,000 shares, became exercisable in five equal annual installments beginning on September 11, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $119.80 | $0.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · derivative · entry 10 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 35,000 shares Expires 2024-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 35,000 shares, became exercisable in five equal annual installments beginning on September 10, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 12,024 | $273.00 | $3,282,552.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,360 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 15,000 | $159.32 | $2,389,800.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 12,274 | $273.00 | $3,350,802.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,384 Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Exercise / conversionBio-Rad B Common Stock | 16,000 | $139.56 | $2,232,960.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 3 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 2, 2023 15:28 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | Tax withholdingBio-Rad B Common Stock | 25,642 | $273.00 | $7,000,266.00 |
DisclosureSEC source: 0001062993-23-020015 · form4.xml · nonDerivative · entry 2 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,658 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.